Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (131-140 of 349) with videos related to

Pageof 35
Sort By:
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
American Heart Journal|December 25, 2015
Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trialsJosephine Warren, Roxana Mehran, Usman Baber, et al.
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
Lancet (London, England)|September 3, 2020
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
Clinical Cardiology|January 23, 2020
Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR AsiaYanan Zou, Shuang Yang, Shipeng Wang, et al.
European Journal of Heart Failure|April 17, 2023
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillationGerasimos Filippatos, Dimitrios Farmakis, Javed Butler, et al.
European Journal of Heart Failure|May 6, 2020
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysisDavid Messika-Zeitoun, Patrick Verta, John Gregson, et al.
European Journal of Heart Failure|February 21, 2020
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trialsXavier Rossello, João Pedro Ferreira, Stuart J Pocock, et al.
Pageof 35

Showing results (131-140 of 349) with videos related to

Sort By:
Pageof 35
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
American Heart Journal|December 25, 2015
Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trialsJosephine Warren, Roxana Mehran, Usman Baber, et al.
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
Lancet (London, England)|September 3, 2020
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
Clinical Cardiology|January 23, 2020
Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR AsiaYanan Zou, Shuang Yang, Shipeng Wang, et al.
European Journal of Heart Failure|April 17, 2023
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillationGerasimos Filippatos, Dimitrios Farmakis, Javed Butler, et al.
European Journal of Heart Failure|May 6, 2020
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysisDavid Messika-Zeitoun, Patrick Verta, John Gregson, et al.
European Journal of Heart Failure|February 21, 2020
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trialsXavier Rossello, João Pedro Ferreira, Stuart J Pocock, et al.
Pageof 35